Holen Sie sich die Stockscreener-App
23.93
7.39%
-1.91
Handel nachbörslich:
24.17
0.24
+1.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SAVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.84
Offen:
$25.54
24-Stunden-Volumen:
1.89M
Relative Volume:
0.87
Marktkapitalisierung:
$1.15B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
-10.93
EPS:
-2.19
Netto-Cashflow:
$-82.44M
1W Leistung:
-9.77%
1M Leistung:
-11.63%
6M Leistung:
+8.53%
1J Leistung:
+5.42%
1-Tages-Spanne:
$23.45
$25.70
1-Wochen-Bereich:
$23.45
$26.70
52-Wochen-Spanne:
$8.79
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Firmenname
Cassava Sciences Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten
Cassava Sciences (NASDAQ:SAVA) Trading Down 5.8%Should You Sell? - MarketBeat
Unpacking the Latest Options Trading Trends in Cassava Sciences - Benzinga
Analysts Believe Cassava Sciences Now Has 300% Upside From Here - MSN
Cassava Sciences (SAVA) Scheduled to Post Earnings on Thursday - MarketBeat
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 - GlobeNewswire
International Assets Investment Management LLC Makes New Investment in Cassava Sciences, Inc. (NASDAQ:SAVA) - MarketBeat
Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value - Yahoo Finance
Long Term Trading Analysis for (SAVA) - Stock Traders Daily
Cassava Sciences Inc (SAVA-Q) QuotePress Release - The Globe and Mail
HC Wainwright & Co. Upgrades Cassava Sciences (SAVA) - MSN
Cassava Sciences Options Trading: A Deep Dive into Market Sentiment - Benzinga
Institutions profited after Cassava Sciences, Inc.'s (NASDAQ:SAVA) market cap rose US$72m last week but individual investors profited the most - Simply Wall St
(SAVA) Proactive Strategies - Stock Traders Daily
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge - Insider Monkey
Cassava Sciences (NASDAQ:SAVA) Trading 5.1% HigherWhat's Next? - MarketBeat
HC Wainwright Comments on Cassava Sciences, Inc.'s FY2025 Earnings (NASDAQ:SAVA) - MarketBeat
After Cassava Fraud Indictment, Questioning the Ethics of Simufilam Trial - Being Patient
Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement - Yahoo Finance
Cassava Sciences: Phase III trials storm ahead amid controversy - Yahoo Finance
(SAVA) Long Term Investment Analysis - Stock Traders Daily
Cassava Sciences Stock Jumps After CEO’s Update On Alzheimer’s Drug Trial: Retail Sentiment Wavers - Barchart
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August - Benzinga
Cassava Sciences (NASDAQ:SAVA) Shares Gap UpTime to Buy? - MarketBeat
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? - Benzinga
Cassava Sciences earns rare buy as H.C. Wainwright upgrades post settlement - MSN
Why Is Bio-Path Holdings Stock Soaring On Tuesday?Cassava Sciences (NASDAQ:SAVA) - Benzinga
Cassava Sciences stock upgraded at H.C. Wainwright (NASDAQ:SAVA) - Seeking Alpha
Cassava Sciences (NASDAQ:SAVA) Lifted to Buy at HC Wainwright - MarketBeat
Cassava agrees to $40M settlement over misleading Alzheimer’s clinical trial statements - Top Class Actions
An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped? - BioPharma Dive
Cassava's Alzheimer's Therapy: A Confidence Bet - Seeking Alpha
SEC brings securities fraud charges against Cassava Sciences - JD Supra
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session - MSN
SAVA Stock Down On Settling Misleading Alzheimer's Study Data Claims - Barchart
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims - Zacks Investment Research
Company News for Sep 30, 2024 - Yahoo Finance
SEC charges Cassava over 'misleading' Alzheimer's claims - pharmaphorum
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, and More - MSN
Cassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA) - MarketBeat
Why Cassava Sciences Stock Dived by Almost 11% Today - MSN
(SAVA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Stocks to Watch Friday: Bristol-Myers Squibb, Costco, Cassava Sciences, EchoStar - The Wall Street Journal
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement - MSN
Bristol Myers, Costco, EchoStar, DJT, Wynn, HP Inc., and More Stock Movers - Barron's
Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims - Yahoo Finance
Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more - CNBC
Cassava Sciences (NASDAQ:SAVA) Shares Gap Down to $31.87 - MarketBeat
Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):